1 Report Prologue 2 Market Introduction 2.1 Definition 2.2 Scope of Study 2.3 Research Objective 2.4 Assumptions & Limitations 2.4.1 Assumptions 2.4.2 Limitations 2.5 Market Structure 3 Research Methodology 3.1 Research Process 3.2 Primary Research 3.3 Secondary Research 4 Market Dynamics 4.1 Introduction 4.2 Drivers 4.2.1 Increasing Cancer Survival Rate 4.2.2 Growing Demand for Advanced Therapies 4.2.3 Less Number of Side Effects as Compared to Conventional Treatment Methods 4.2.4 Growth of Cancer Healthcare Facilities in Emerging Countries 4.2.5 Changing Lifestyle and Increasing Smoking Population in Middle East & Africa 4.3 Restraints 4.3.1 High cost of Cancer Biological Therapy 4.4 Opportunities 4.4.1 UnTapped Types of Cancers 5 Market Factor Analysis 5.1 Porter’s Five Forces Model 5.1.1 Bargaining power of suppliers 5.1.2 Bargaining Power of Buyers 5.1.3 Threat of New Entrants 5.1.4 Threat of Substitutes 5.1.5 Intensity of Rivalry 6 Global Cancer Biological Therapy Market, by phases 6.1 Introduction 6.2 Phases 7 Global Cancer Biological Therapy Market, by Application 7.1 Introduction 7.2 Monoclonal Antibodies 7.3 Interferons 7.4 Interleukins 7.5 Cancer growth inhibitors 7.6 Gene Therapy 7.7 Colony-Stimulating Factors 8 Global Cancer Biological Therapy Market, by End Users 8.1 Introduction 8.2 Hospitals & Clinics 8.3 Cancer Research Centers 8.4 Laboratories 9 Global Cancer Biological Therapy Market, by Region 9.1 Introduction 9.2 North America 9.2.1 US 9.2.2 Canada 9.3 Europe 9.3.1 Germany 9.3.2 France 9.3.3 U.K. 9.3.4 Italy 9.3.5 Spain 9.3.6 Rest of Europe 9.4 Asia-Pacific 9.4.1 Japan 9.4.2 China 9.4.3 India 9.4.4 Republic of Korea 9.4.5 Rest of Asia-Pacific 9.5 Middle East & Africa 9.5.1 Middle East 9.5.2 Africa 12 Competitive Landscape 12.1 Company Share Analysis 13 Company Profiles 13.1 Amgen Inc. 13.1.1 Company Overview 13.1.2 Product/Business Overview 13.1.3 Adherium Health: Financials 13.1.4 Key Developments 13.1.5 SWOT Analysis 13.2 Bristol-Myers Squibb 13.2.1 Company Overview 13.2.2 Product overview 13.2.3 Financial Overview 13.2.4 Key Developments 13.2.5 SWOT Analysis 13.3 Celgene Corporation 13.3.1 Company Overview 13.3.2 Product Overview 13.3.3 Financial Overview 13.3.4 Key Development 13.3.5 SWOT Analysis 13.4 ELI Lilly and Company 13.4.1 Company Overview 13.4.2 Product Overview 13.4.3 Financial Overview 13.4.4 Key Developments 13.4.5 SWOT Analysis 13.5 EnGeneIC Ltd 13.5.1 Company Overview 13.5.2 Product overview 13.5.3 Financial Overview 13.5.4 Key Developments 13.5.5 SWOT Analysis